Is the domestic bivalent HPV vaccine cost-effective compared with quadrivalent or nine-valent HPV vaccines in the context of cervical cancer screening? A modeling study.

ABSTRACT:

Background

The World Health Organization (WHO) released the Global Strategy for Accelerated Elimination of Cervical Cancer (GSAICC), which points out that low- and middle-income countries are in a difficult situation in terms of the cervical cancer prevention challenge, and that the focus should be on the economics of prevention strategies. In the context of cervical cancer screening, it is unclear whether China's self-developed, domestically produced bivalent HPV vaccine is economical compared to quadrivalent and nine-valent HPV vaccines.

Objectives

To evaluate the cost-effectiveness of bivalent HPV vaccine compared with quadrivalent and nine-valent HPV vaccines in China in the context of cervical cancer screening in China, and to provide a basis for the development of cerv

SUBMITTER: Zhang L 

PROVIDER: S-EPMC12781823 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature